136 related articles for article (PubMed ID: 1735736)
1. Factors influencing the response and survival of patients with liver metastases from breast cancer receiving OK-432-combined adoptive immunotherapy.
Yamasaki S; Okino T; Kan N; Satoh K; Mise K; Teramura Y; Harada T; Kodama H; Hori T; Ohgaki K
J Cancer Res Clin Oncol; 1992; 118(2):157-62. PubMed ID: 1735736
[TBL] [Abstract][Full Text] [Related]
2. Bone metastasis as a prognostic factor in breast cancer patients with liver metastasis given OK-432-combined adoptive immunotherapy via the hepatic artery.
Kan N; Yamasaki S; Kodama H; Okino T; Ichinose Y; Moriguchi Y; Li L; Sugie T; Imamura M
Biotherapy; 1993; 6(4):245-50. PubMed ID: 8018445
[TBL] [Abstract][Full Text] [Related]
3. [Analysis of long-term (5-year) survival in patients with metastatic breast cancer to the liver].
Kan N
Gan To Kagaku Ryoho; 2006 Nov; 33(12):1780-4. PubMed ID: 17212106
[TBL] [Abstract][Full Text] [Related]
4. The therapeutic effect of OK-432-combined adoptive immunotherapy against liver metastases from gastric or colorectal cancers.
Satoh K; Kan N; Okino T; Mise K; Yamasaki S; Harada T; Hori T; Ohgaki K; Tobe T
Biotherapy; 1993; 6(1):41-9. PubMed ID: 8507544
[TBL] [Abstract][Full Text] [Related]
5. OK-432-combined adoptive immunotherapy as a prognostic factor in peritoneal metastasis from gastric cancer.
Mise K; Kan N; Okino T; Moriguchi Y; Harada T; Ichinose Y; Inoue K
Surg Today; 1994; 24(1):54-8. PubMed ID: 8054776
[TBL] [Abstract][Full Text] [Related]
6. The therapeutic effect of OK-432-combined adoptive immunotherapy against liver metastases from breast cancer.
Okino T; Kan N; Nakanishi M; Satoh K; Mise K; Teramura Y; Yamasaki S; Hori T; Kodama H; Ohgaki K
J Cancer Res Clin Oncol; 1990; 116(2):197-202. PubMed ID: 2324164
[TBL] [Abstract][Full Text] [Related]
7. [The therapeutic effects of OK-432 combined adoptive immunotherapy (AIT) against liver metastases of breast cancer].
Okino T; Kan N; Nakanishi M; Satoh K; Mise K; Yamasaki S; Teramura Y; Hori T; Kodama H; Ohgaki K
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-3):1913-9. PubMed ID: 2730083
[TBL] [Abstract][Full Text] [Related]
8. Intrapleural adaptive immunotherapy for breast cancer patients with cytologically-confirmed malignant pleural effusions: an analysis of 67 patients in Kyoto and Shiga Prefecture, Japan.
Kan N; Kodama H; Hori T; Takenaka A; Yasumura T; Kato H; Ogawa H; Mukaihara S; Kudo T; Ohsumi K
Breast Cancer Res Treat; 1993 Sep; 27(3):203-10. PubMed ID: 8312578
[TBL] [Abstract][Full Text] [Related]
9. Relationship between immunological parameters and survival of patients with liver metastases from breast cancer given immuno-chemotherapy.
Yamasaki S; Kan N; Harada T; Ichinose Y; Moriguchi Y; Li L; Sugie T; Kodama H; Satoh K; Ohgaki K
Breast Cancer Res Treat; 1993; 26(1):55-65. PubMed ID: 8400324
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic and life-prolonging effect of intrapleural injection with a streptococcal preparation, OK-432, and IL2-cultured effusion lymphocytes to breast cancer patients with malignant pleural effusion.
Hori T; Mise K; Kan N; Okino T; Satoh K; Yamasaki S; Teramura Y; Harada T; Ohgaki K; Kodama H
Biotherapy; 1992; 5(1):21-9. PubMed ID: 1389900
[TBL] [Abstract][Full Text] [Related]
11. [Improved therapeutic effect of sequential immunotherapy with cyclophosphamide, large doses of OK-432 and recombinant interleukin-2 in breast cancer patients with disseminated metastatic liver tumors].
Akimoto M; Nishihira T; Hirakawa H; Abe M; Ohuchi N; Mori S; Kumagai K
Nihon Geka Gakkai Zasshi; 1991 Jan; 92(1):64-74. PubMed ID: 2014029
[TBL] [Abstract][Full Text] [Related]
12. [Loco-regional immunotherapy with OK-432 and cultured autologous lymphocytes for patients with metastatic cancer].
Kan N; Imamura M
Hum Cell; 1993 Jun; 6(2):100-5. PubMed ID: 8217947
[TBL] [Abstract][Full Text] [Related]
13. [Effect of peri-operatively administrated OK-432 on immunopotency in primary liver cancer--immunological and histological study in cases receiving intrahepatic arterial administration].
Taniwaki S
Nihon Shokakibyo Gakkai Zasshi; 1990 Apr; 87(4):1020-7. PubMed ID: 2376898
[TBL] [Abstract][Full Text] [Related]
14. [Analysis of 5-year survival among breast cancer patients with malignant pleural effusion receiving intrapleural OK-432 followed by adoptive transfer with cultured effusion lymphocytes].
Kan N
Gan To Kagaku Ryoho; 2003 Oct; 30(11):1559-61. PubMed ID: 14619463
[TBL] [Abstract][Full Text] [Related]
15. [Intrapleural administration with OK-432 and cultured autologous pleural effusion lymphocytes for breast cancer patients with malignant pleural effusions: analysis of 84 patients over a 14-year period].
Kan N
Gan To Kagaku Ryoho; 1999 Oct; 26(12):1796-800. PubMed ID: 10560397
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy using the streptococcal preparation OK-432 for the treatment of uterine cervical cancer. Cervical Cancer Immunotherapy Study Group.
Cancer; 1987 Nov; 60(10):2394-402. PubMed ID: 2889522
[TBL] [Abstract][Full Text] [Related]
17. [A long-survival case of hepatocellular carcinoma treated by intra-arterial chemotherapy and immunotherapy].
Nagano H; Sasaki Y; Imaoka S; Shibata T; Wada H; Ishikawa O; Ohigashi H; Kabuto T; Hurukawa H; Fukuda I
Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 2):2961-4. PubMed ID: 2551235
[TBL] [Abstract][Full Text] [Related]
18. [Experimental and clinical study of adoptive immunotherapy combined with preadministration of OK-432: a method to augment the therapeutic effect].
Kan N; Okino T; Nakanishi M; Sato K; Mise K; Teramura Y; Yamasaki S; Hori T; Ohgaki K; Tobe T
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1455-61. PubMed ID: 2786379
[TBL] [Abstract][Full Text] [Related]
19. [Transarterial immuno-chemotherapy including adoptive transfer of autologous cultured lymphocytes for stage IV breast cancer patients with locally-advanced tumor].
Kan N; Harada T; Kodama H; Ichinose Y; Moriguchi Y; Sugie T; Li L; Sato K; Imamura M
Gan To Kagaku Ryoho; 1993 Aug; 20(11):1593-6. PubMed ID: 8373227
[TBL] [Abstract][Full Text] [Related]
20. Combined immunotherapy with intracavital injection of activated lymphocytes, monocyte-derived dendritic cells and low-dose OK-432 in patients with malignant effusion.
Morisaki T; Matsumoto K; Kuroki H; Kubo M; Baba E; Onishi H; Tasaki A; Nakamura M; Inaba S; Katano M
Anticancer Res; 2003; 23(6a):4459-65. PubMed ID: 14666734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
